IGV-001

IGV-001 is Imvax's personalized autologous whole-tumor-derived immunotherapy and biologic-device combination product for newly diagnosed glioblastoma. It is manufactured from each patient's resected glioblastoma cells, which are treated ex vivo with the IGF-1R antisense oligonucleotide IMV-001, irradiated, and placed in implantable biodiffusion chambers. The chambers are temporarily implanted in the abdominal wall, allowing tumor-derived antigens and immunostimulatory signals to diffuse out while preventing intact tumor-cell escape. The approach is intended to induce immunogenic cell death, tumor-antigen presentation, and durable innate and adaptive antitumor immunity before radiotherapy plus temozolomide. Imvax reported Phase 2b top-line data in December 2025 from 99 patients, including median overall survival of 20.3 months with IGV-001 versus 14.0 months with placebo; IGV-001 is not approved for marketing. ([imvax.com](https://www.imvax.com/imvax-announces-positive-top-line-data-from-phase-2b-clinical-trial-of-igv-001-in-newly-diagnosed-gbm/))